From 2009 to 2017, 309 HCC patients had complete data for analysis (among the 340 recruited patients, 11 patients’ RSAD2 mRNA levels could not be determined, and 20 patients had incomplete HRQoL data). This evidence concerns the gene RSAD2 and hepatocellular carcinoma.